磷酸二酯酶-4抑制剂阿普司特  

A phosphodiesterase-4 inhibitor apremilast

作　　者：赵倩 孙悦[2] 石玉[3] 魏波[3] 邹美香[3] 孙铁民[2] 李祎亮[3] 

机构地区：[1]天津市鼓楼社区卫生服务中心西北角医院,天津300102 [2]沈阳药科大学,辽宁沈阳110016 [3]天津药物研究院天津市新药设计与发现重点实验室,天津300193

出　　处：《现代药物与临床》2014年第4期428-433,共6页Drugs & Clinic

基　　金：天津市科技计划项目(13ZCZDSY00100)

摘　　要：银屑病是一种常见的皮肤疾病,其特征是慢性炎症性病变,长期困扰患者且不易为医生治疗。虽然有多种治疗方案可供选择,但都有其局限性,因此急需一种有效、安全的口服治疗银屑病的药物。阿普司特作为磷酸二酯酶-4(PDE-4)抑制剂,是一种口服药物,抑制参与银屑病发病机制中的多个炎症标志物的活性,可有效治疗银屑病。阿普司特在一系列临床研究中显示出良好的治疗前景,且安全性及耐受性均较好。Psoriasis is a common skin disorder characterized by chronic inflammatory lesions. Patients are frequently troubled by it and it is difficult for doctor to cure. Although multiple therapeutic options are available, they all have limitations. There is an urgent need for an effective, safe, and oral drug used in clinic for the treatment of psoriasis. Apremilast, as an inhibitor of phosphodiesterase-4 （PDE-4）, is an oral medication that inhibits the activity of multiple inflammatory markers involved in the pathogenesis of psoriasis. It can be used to treat psoriasis effectively, which shows a good prospect in a series of clinical studies with good safety and tolerability.

关 键 词：阿普斯特 磷酸二酯酶-4抑制剂 银屑病 口服靶向药物 

分 类 号：R287.6[医药卫生—中药学]